Ibritumomab Tiuxetan and Kisqali Femara Co-Pack 400 mg-2.5 mg Dose
Determining the interaction of Ibritumomab Tiuxetan and Kisqali Femara Co-Pack 400 mg-2.5 mg Dose and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: ibritumomab
Brand name: Y-90 Zevalin, In-111 Zevalin
Synonyms: Ibritumomab
Generic Name: letrozole / ribociclib
Brand name: Kisqali Femara Co-Pack 200 mg-25 mg Dose, Kisqali Femara Co-Pack 400 mg-25 mg Dose, Kisqali Femara Co-Pack 600 mg-25 mg Dose
Synonyms: Kisqali Femara Co-Pack 200 mg-2.5 mg Dose, Kisqali Femara Co-Pack
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ibritumomab Tiuxetan-Kisqali Femara Co-Pack 600 mg-2.5 mg Dose
- Ibritumomab Tiuxetan-Kitabis Pak
- Ibritumomab Tiuxetan-Kitabis Pak inhalation
- Ibritumomab Tiuxetan-Klofensaid II
- Ibritumomab Tiuxetan-Klonopin
- Ibritumomab Tiuxetan-Klonopin Wafer
- Kisqali Femara Co-Pack 400 mg-2.5 mg Dose-Ibrutinib
- Kisqali Femara Co-Pack 400 mg-2.5 mg Dose-Ibrutinib Capsules
- Kisqali Femara Co-Pack 400 mg-2.5 mg Dose-Ibrutinib Tablets
- Kisqali Femara Co-Pack 400 mg-2.5 mg Dose-Ibu
- Kisqali Femara Co-Pack 400 mg-2.5 mg Dose-IBU Tablets
- Kisqali Femara Co-Pack 400 mg-2.5 mg Dose-Ibu-2